Table 4

Series of SMZL patients treated with rituximab-based approach

Response
ReferenceYearStudy typeSchemePatient statusNORRDurationOS
Rituximab monotherapy
 Bennett et al82,1022005RetrospectiveR monotherapyRR1191%PFS 60% at 5 y70% at 5 y
 Tsimberidou et al702006RetrospectiveR monotherapyFirst line2588%FFS 86% at 3 y95% at 3 y
 Kalpadakis et al83,962007RetrospectiveR monotherapyFirst line16100%PFS 92% at 2.4 y100% at 2.1 y
 Else et al1032012RetrospectiveR monotherapyFirst line and RR10100%DFS 89% at 3 yNR
 Kalpadakis et al732013RetrospectiveR monotherapyFirst line5895%PFS 73% at 5 y92% at 5 y
Rituximab + chemotherapy
 Tsimberidou et al702006RetrospectiveR-chemoFirst line683%FFS 100% at 3 y100% at 3 y
 Cervetti et al85,862010RetrospectiveR-2CDAFirst line and RR47*87%PFS 80% at 5 y86% at 5 y
 Else et al1032012RetrospectiveR-chemoFirst line and RR33100%DFS 71% at 3 yNR
 Iannitto et al872015ProspectiveR-COMPFirst line5184%PFS 54% at 6 y72% at 6 y
  • 2CDA, 2-chlorodeoxyadenosine; chemo, chemotherapy; DFS, disease-free survival; R, rituximab; RR, relapsed/refractory.

  • * Rituximab in 32 patients.